ニュース

北京、2021年5月18日-Lepu Medical Technology (Beijing) Co. 、Ltd。(「Lepu Medical」) は、ハイテク医療機器および機器の開発、製造、およびマーケティングを専門とするグローバルな大手企業であり、 5月14日、仮想「検出のためのCOVID-19方法に関するセミナー」を主催し、理論とベストプラクティスを共有して、中国および世界中で世界的なCOVID-19管理と予防をさらに促進しました。

The seminar, which included a virtual training session and a virtual visit to Lepu Medical’s headquarters in Beijing, was part of the seven-day “Seminar on COVID-19 Methods For Detection,” sponsored by China’s Ministry of Commerce and organized by Beijing Holley-Cotect Pharmaceuticals Co., Ltd. The seminar aimed to help other countries and regions to control the pandemic by sharing China’s advanced prevention and control experience. 

ライブストリーミングビデオを介して事実上開催されたセミナーには、質疑応答セッション、共有セミナー、クラウド訪問、およびその他の仮想形式が含まれていました。 ケニア、モーリシャス、ベネズエラ、ペルー、ウクライナ、スリランカ、イラク、エチオピア、イランを含む9か国の科学研究機関の医療従事者、政府職員、研究者を含む合計77人の参加者が、Lepuが主催する講演とクラウド訪問に参加しました。医療。

During the seminar, Lepu Medical invited Dr. Jing Yu from the Wuhan Hospital of Traditional Chinese and Western Medicine to deliver a training lecture on basic knowledge and practical experiences of SARS-COV-2 detection, antigen rapid tests, and biochemical indicators for diagnosis. The training course covered the closed loop and seamless SARS-COV-2 detection process from sampling, sample transfer, sample receipt, testing, result reporting and medical waste treatment in various settings including medical institutions, communities, mass screening sites and public places. The seminar, which was well-received by attendees, included a question and answer session in which Dr. Jing Yu and representatives from Lepu Medical answered detailed questions on COVID-19 detection methods, and provided best practice advice to attendees. 

Lepu Medical’s 2019-nCoV抗原急速なテストキット (コロイド金免疫クロマトグラフィー), a simple screening method for COVID-19 that delivers quick results with high negative predictive value (NPV), was held up as an example by Dr. Yu during the training session. The antigen test method, which is non-invasive, simple to use, cost-efficient, convenient, rapid, stable and accurate has shown high sensitivity of 95.06% and high specificity of 99.62% in clinical trials in IPE Center for Clinical Laboratory, a Lepu Medical subsidiary. Results can be quickly retrieved in 15 minutes. Lepu Medical provides both Lepu Professional Antigen test kits for use by medical institutions and Lepu Antigen self-test kits for individual self-test use, to support diverse testing needs. The Lepu Antigen self-test kit is already approved by BfArM and available in Germany. 

“(For the antigen rapid test,) the positive results can be seen in the early stage after the symptoms (emerged) or in the infection,” said Dr. Yu, addressing participant questions raised about test timing and sensitivity during the lively Q&A session following her lecture, “The sensitivity of the antigen detection depends on the prevalence of the virus. The positive rate of the antigen rapid test is useful in the high prevalent area. If the viral load of the sample is high, the sensitivity of the antigen test and PCR test can be the same.  All biomarkers combined together can be the most effective.”

In addition to the 2019-nCoV抗原急速なテストキット (コロイド金免疫クロマトグラフィー), Lepu Medical offers other comprehensive diagnostic solutions including nucleic acid series products and solutions, which provide standard tests for COVID-19 diagnosis, and neutralization antibody test products to detect the effectiveness of COVID-19 vaccines in the post-pandemic period. Other COVID-19 products and solutions include sample collection kits, manual sample extraction kits, automated sample extractors, nucleic acid test kits, real-time PCR systems for standard clinical nucleic acid diagnostics, and antibody test kits and systems for vaccine effect evaluation.

Lepu Medical has been providing proactive support to control the COVID-19 pandemic from an early stage. In early 2020, during the outbreak in China, Lepu Medical started emergency production of medical equipment supplies and donated more than RMB5 million of personal protective equipment (PPE), medical devices and cash to severely impacted areas. The company also developed an online free medical consulting system “Doctor Lepu” to assist patients remotely while supporting social distancing. Lepu Medical subsidiaries also dispatched volunteers and a medical aid team to the city of Wuhan and provided mass COVID-19 nucleic acid testing in Beijing where the company is headquartered. Lepu Medical’s products were also widely used across China’s hospitals, medical centers and COVID-19 testing sites. These products included Lepu Medical’s automatic PCR analysis system, personal forehead thermometers, pulse oximeters, monitors, electrocardiographs, household oxygen generators and pharmaceutical products.

Lepu Medicalは、20を超えるグローバルOEMパートナーを擁する80を超える国と地域をカバーするグローバル企業として、研究開発、製造、流通のグローバルネットワークとリソースを活用して、COVID-19に対抗するための世界的な取り組みをサポートしてきました。 同社のさまざまな関連製品は、ヨーロッパでCE証明書を付与され、米国食品医薬品局 (FDA) によって承認され、パンデミックと戦うために140か国以上に配布されています。 Lepu Medicalは、複数の国での定期的な集団検査をサポートし、2021年1月から全国的な検査を実施するために2,000万を超える抗原検査キットを提供することにより、オーストリアの学校の組織的な再開を支援してきました。 中国の輸出ホワイトリストにリストされているLepu SARS-CoV-2抗原急速検査キットは、ドイツの公式研究所PEIによって認定されており、自己検査のためにドイツ連邦医薬品医療機器研究所 (BfArM) によって特別な承認が与えられています。

Upholding the company’s spirit of integrity, quality and scientific innovation, Lepu Medical will continue to focus on combating the COVID-19 pandemic and go above and beyond to provide the best quality of products and services to satisfy the needs of healthcare professionals and patients.